Rituximab Market Analysis

  • Report ID: 3315
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Rituximab Market Analysis

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

The hospital pharmacies segment in the rituximab market is expected to garner the largest revenue during the forecast period. Due to the growing use of rituximab for cancer therapy in hospitals, the hospital pharmacies segment is expected to account for a total market share of 39.7% by 2037. The dominant position of the sector is expected to be achieved during the forecast period by rising healthcare spending around the world, increased awareness levels for patients, and availability of superior hospital infrastructure in high-income countries.

Application (Blood Cancer, Rheumatoid Arthritis, Wegener’s Granulomatosis)

The blood cancer segment is expected to hold 24% share of the global rituximab market by 2037. Nearly every 3 minutes, one person in the US is diagnosed with blood cancer. Leukaemia was the sixth most frequent cause of cancer deaths in men from 2013 to 2017 and the seventh most frequent cause in women in the US. Also, the increased funding and investment in healthcare mostly in cancer is driving the growth of the market. The cases associated with blood cancer are expected to increase in the upcoming years due to lifestyle factors which will significantly boost the market growth of rituximab.

Our in-depth analysis of the global market includes the following segments:

     Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

     Application

  • Blood Cancer
  • Rheumatoid Arthritis
  • Wegener’s Granulomatosis
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3315
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of rituximab is estimated at USD 5.11 billion.

The rituximab market size was over USD 4.03 billion in 2024 and is anticipated to cross USD 27.13 billion by 2037, witnessing more than 15.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for monoclonal antibodies, increasing collaborations for the development of new products and investment in healthcare sector will drive the market growth.

North America industry is anticipated to dominate majority revenue share of 45% by 2037, fuelled by increased government spending on cancer research as well as the presence of major pharmaceutical companies in the region.

The major players in the market are Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample